- Based on the Independent Data Monitoring Committee's recommendation, Boehringer Ingelheim and Eli Lilly And Co (NYSE:LLY) will stop early its EMPA-KIDNEY trial of Jardiance (empagliflozin) in adults with chronic kidney disease (CKD).
- This follows a formal interim assessment that met prespecified criteria for positive efficacy.
- As the largest SGLT2 inhibitor trial in CKD to date, the 6,600-subject EMPA-KIDNEY is evaluating the efficacy and safety of Jardiance in adults with CKD who are frequently seen in clinical practice but who have been under-represented in previous SGLT2 inhibitor trials.
- Read Next: Eli Lilly To Suspend Sale Of 'Non-Essential' Medicines To Russia.
- In March 2020, the FDA granted Fast Track designation to the clinical investigation of Jardiance to reduce the risk of kidney disease progression and cardiovascular death in adults with CKD.
- Full results from the EMPA-KIDNEY trial will be presented at an upcoming medical congress.
- Price Action: LLY shares are up 0.20% at $276 during the market session on the last check Wednesday.
